Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indian biosimilars guidelines go on stream amid implementation concerns

This article was originally published in Scrip

Executive Summary

India is set to implement its first set of guidelines on biosimilars next month, lending much-needed clarity to the approval pathway for such products, though concerns persist on whether the country's regulatory machinery is geared to implement these effectively.

You may also be interested in...



Here’s What Competition Looks Like In India’s Humira Biosimilars Market

Competition may be just readying to jump in and gnaw into Humira’s share in Europe later this year, but the Indian market for biosimilar adalimumab already has more than half a dozen players, with distinct pricing characteristics. Scrip takes a peek into the competitive market.

Here’s What Competition Looks Like In India’s Humira Biosimilars Market

Competition may be just readying to jump in and gnaw into Humira’s share in Europe later this year, but the Indian market for biosimilar adalimumab already has more than half a dozen players, with distinct pricing characteristics. Scrip takes a peek into the competitive market.

APAC Cancer Preparedness Varied, Late Diagnosis A Key Challenge

A new report on the preparedness of 10 APAC nations to tackle a mounting cancer burden identifies gaps that need to be addressed, saying that a focus on prevention and early diagnosis could help, while also touching on issues around regional drug availability.

Topics

Related Companies

UsernamePublicRestriction

Register

MT125711

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel